| Literature DB >> 18850022 |
A E Hallack Neto1, F L Dulley, S A Coelho Siqueira, L F Pracchia, M Belesso, R Saboya, D Sturaro, J U Amigo-Filho, A Mendrone Junior, D A F Chamone, J Pereira.
Abstract
A total of 53 patients aged 18-60 years with high-intermediate or high-risk diffuse large B-cell lymphoma (DLBCL) were evaluated to analyze the impact of the cell of origin. Of 53 patients, 16 underwent autologous SCT (ASCT) in first remission and the rest received conventional chemotherapy. Immunohistochemistry was evaluated in 47 cases: 17 were of germinal center (GC) origin and 30 were of non-GC origin. There was no survival difference between the two groups. Overall survival (OS) and disease-free survival (DFS) at 3 years were 93 and 83%, respectively, for the 14 patients who underwent ASCT. Their DFS was significantly better than that of patients who achieved CR but did not undergo ASCT. We conclude that ASCT is safe and improves the DFS of high-intermediate and high-risk DLBCL, regardless of the cell of origin. This observation should be confirmed in a larger study.Entities:
Mesh：
Substances：
Year: 2008 PMID： 18850022 DOI： 10.1038/bmt.2008.330
Source DB: PubMed Journal: Bone Marrow Transplant ISSN： 0268-3369 Impact factor: 5.483